Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer

A. A. Adjei, A. Argiris, J. R. Murren, Fossella, Green, Eckardt, Wozniak, Socinsky

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Single-agent activity has been observed for both docetaxel and irinotecan in several solid tumors, including non-small cell lung cancer (NSCLC). Compilation of data from phase II trials of single-agent docetaxel therapy in NSCLC yielded overall response rates of 26% and a 1-year survival rate of 52%. Furthermore, a recent study that combined radiotherapy with concurrent docetaxel treatment reported an overall response rate of 77%. The most important adverse effect of docetaxel therapy is neutropenia. Phase II trials of single-agent irinotecan for NSCLC patients resulted in response rates of 15% to 31%. The main toxicities were neutropenia and diarrhea. Investigators have begun to explore the efficacy of combining docetaxel and irinotecan. The results of preclinical studies suggest that schedule and order of administration may be important. A Japanese study evaluated the combination in previously untreated patients with NSCLC, and found eight partial responses in 26 patients (32%). A recent phase I study at the Mayo Clinic showed partial responses in three of five patients who received irinotecan followed by docetaxel. In a phase I study conducted at Yale Cancer Center, escalating doses of docetaxel (25 to 40 mg/m2) were given before irinotecan (50 mg/m2) for 4 weeks followed by a 2-week rest. There was one partial response among five evaluable patients with NSCLC (one of four among patients who had received no prior chemotherapy). The results of these studies suggest that the combination of docetaxel and irinotecan shows promise in the treatment of NSCLC. Irinotecan also has been used in combination with other chemotherapeutic agents. The irinotecan/etoposide combination has been less extensively evaluated but thus far appears to be associated with considerable toxicity, particularly myelosuppression, without clear therapeutic advantage. One report of the use of the triple combination of irinotecan/cisplatin/etoposide resulted in 16 partial responses in 42 NSCLC patients (38%). Like docetaxel, irinotecan has been used effectively in conjunction with radiation therapy, with partial response rates in some studies of more than 70%.

Original languageEnglish (US)
Pages (from-to)32-42
Number of pages11
JournalSeminars in Oncology
Volume26
Issue number5 SUPPL. 16
StatePublished - 1999
Externally publishedYes

Fingerprint

irinotecan
docetaxel
Non-Small Cell Lung Carcinoma
Therapeutics
Etoposide
Neutropenia
Radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Adjei, A. A., Argiris, A., Murren, J. R., Fossella, Green, Eckardt, ... Socinsky (1999). Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer. Seminars in Oncology, 26(5 SUPPL. 16), 32-42.

Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer. / Adjei, A. A.; Argiris, A.; Murren, J. R.; Fossella; Green; Eckardt; Wozniak; Socinsky.

In: Seminars in Oncology, Vol. 26, No. 5 SUPPL. 16, 1999, p. 32-42.

Research output: Contribution to journalArticle

Adjei, AA, Argiris, A, Murren, JR, Fossella, Green, Eckardt, Wozniak & Socinsky 1999, 'Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer', Seminars in Oncology, vol. 26, no. 5 SUPPL. 16, pp. 32-42.
Adjei AA, Argiris A, Murren JR, Fossella, Green, Eckardt et al. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer. Seminars in Oncology. 1999;26(5 SUPPL. 16):32-42.
Adjei, A. A. ; Argiris, A. ; Murren, J. R. ; Fossella ; Green ; Eckardt ; Wozniak ; Socinsky. / Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer. In: Seminars in Oncology. 1999 ; Vol. 26, No. 5 SUPPL. 16. pp. 32-42.
@article{0b2824f849504a08bb13706705ad10ae,
title = "Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer",
abstract = "Single-agent activity has been observed for both docetaxel and irinotecan in several solid tumors, including non-small cell lung cancer (NSCLC). Compilation of data from phase II trials of single-agent docetaxel therapy in NSCLC yielded overall response rates of 26{\%} and a 1-year survival rate of 52{\%}. Furthermore, a recent study that combined radiotherapy with concurrent docetaxel treatment reported an overall response rate of 77{\%}. The most important adverse effect of docetaxel therapy is neutropenia. Phase II trials of single-agent irinotecan for NSCLC patients resulted in response rates of 15{\%} to 31{\%}. The main toxicities were neutropenia and diarrhea. Investigators have begun to explore the efficacy of combining docetaxel and irinotecan. The results of preclinical studies suggest that schedule and order of administration may be important. A Japanese study evaluated the combination in previously untreated patients with NSCLC, and found eight partial responses in 26 patients (32{\%}). A recent phase I study at the Mayo Clinic showed partial responses in three of five patients who received irinotecan followed by docetaxel. In a phase I study conducted at Yale Cancer Center, escalating doses of docetaxel (25 to 40 mg/m2) were given before irinotecan (50 mg/m2) for 4 weeks followed by a 2-week rest. There was one partial response among five evaluable patients with NSCLC (one of four among patients who had received no prior chemotherapy). The results of these studies suggest that the combination of docetaxel and irinotecan shows promise in the treatment of NSCLC. Irinotecan also has been used in combination with other chemotherapeutic agents. The irinotecan/etoposide combination has been less extensively evaluated but thus far appears to be associated with considerable toxicity, particularly myelosuppression, without clear therapeutic advantage. One report of the use of the triple combination of irinotecan/cisplatin/etoposide resulted in 16 partial responses in 42 NSCLC patients (38{\%}). Like docetaxel, irinotecan has been used effectively in conjunction with radiation therapy, with partial response rates in some studies of more than 70{\%}.",
author = "Adjei, {A. A.} and A. Argiris and Murren, {J. R.} and Fossella and Green and Eckardt and Wozniak and Socinsky",
year = "1999",
language = "English (US)",
volume = "26",
pages = "32--42",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 16",

}

TY - JOUR

T1 - Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer

AU - Adjei, A. A.

AU - Argiris, A.

AU - Murren, J. R.

AU - Fossella,

AU - Green,

AU - Eckardt,

AU - Wozniak,

AU - Socinsky,

PY - 1999

Y1 - 1999

N2 - Single-agent activity has been observed for both docetaxel and irinotecan in several solid tumors, including non-small cell lung cancer (NSCLC). Compilation of data from phase II trials of single-agent docetaxel therapy in NSCLC yielded overall response rates of 26% and a 1-year survival rate of 52%. Furthermore, a recent study that combined radiotherapy with concurrent docetaxel treatment reported an overall response rate of 77%. The most important adverse effect of docetaxel therapy is neutropenia. Phase II trials of single-agent irinotecan for NSCLC patients resulted in response rates of 15% to 31%. The main toxicities were neutropenia and diarrhea. Investigators have begun to explore the efficacy of combining docetaxel and irinotecan. The results of preclinical studies suggest that schedule and order of administration may be important. A Japanese study evaluated the combination in previously untreated patients with NSCLC, and found eight partial responses in 26 patients (32%). A recent phase I study at the Mayo Clinic showed partial responses in three of five patients who received irinotecan followed by docetaxel. In a phase I study conducted at Yale Cancer Center, escalating doses of docetaxel (25 to 40 mg/m2) were given before irinotecan (50 mg/m2) for 4 weeks followed by a 2-week rest. There was one partial response among five evaluable patients with NSCLC (one of four among patients who had received no prior chemotherapy). The results of these studies suggest that the combination of docetaxel and irinotecan shows promise in the treatment of NSCLC. Irinotecan also has been used in combination with other chemotherapeutic agents. The irinotecan/etoposide combination has been less extensively evaluated but thus far appears to be associated with considerable toxicity, particularly myelosuppression, without clear therapeutic advantage. One report of the use of the triple combination of irinotecan/cisplatin/etoposide resulted in 16 partial responses in 42 NSCLC patients (38%). Like docetaxel, irinotecan has been used effectively in conjunction with radiation therapy, with partial response rates in some studies of more than 70%.

AB - Single-agent activity has been observed for both docetaxel and irinotecan in several solid tumors, including non-small cell lung cancer (NSCLC). Compilation of data from phase II trials of single-agent docetaxel therapy in NSCLC yielded overall response rates of 26% and a 1-year survival rate of 52%. Furthermore, a recent study that combined radiotherapy with concurrent docetaxel treatment reported an overall response rate of 77%. The most important adverse effect of docetaxel therapy is neutropenia. Phase II trials of single-agent irinotecan for NSCLC patients resulted in response rates of 15% to 31%. The main toxicities were neutropenia and diarrhea. Investigators have begun to explore the efficacy of combining docetaxel and irinotecan. The results of preclinical studies suggest that schedule and order of administration may be important. A Japanese study evaluated the combination in previously untreated patients with NSCLC, and found eight partial responses in 26 patients (32%). A recent phase I study at the Mayo Clinic showed partial responses in three of five patients who received irinotecan followed by docetaxel. In a phase I study conducted at Yale Cancer Center, escalating doses of docetaxel (25 to 40 mg/m2) were given before irinotecan (50 mg/m2) for 4 weeks followed by a 2-week rest. There was one partial response among five evaluable patients with NSCLC (one of four among patients who had received no prior chemotherapy). The results of these studies suggest that the combination of docetaxel and irinotecan shows promise in the treatment of NSCLC. Irinotecan also has been used in combination with other chemotherapeutic agents. The irinotecan/etoposide combination has been less extensively evaluated but thus far appears to be associated with considerable toxicity, particularly myelosuppression, without clear therapeutic advantage. One report of the use of the triple combination of irinotecan/cisplatin/etoposide resulted in 16 partial responses in 42 NSCLC patients (38%). Like docetaxel, irinotecan has been used effectively in conjunction with radiation therapy, with partial response rates in some studies of more than 70%.

UR - http://www.scopus.com/inward/record.url?scp=0032722642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032722642&partnerID=8YFLogxK

M3 - Article

C2 - 10585007

AN - SCOPUS:0032722642

VL - 26

SP - 32

EP - 42

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 16

ER -